Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · October 31, 2024

Decitabine, Venetoclax, and Ponatinib for Advanced-Phase CML and Philadelphia Chromosome–Positive AML

The Lancet Haematology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Haematology
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
Lancet Haematol 2024 Sep 17;[EPub Ahead of Print], NJ Short, D Nguyen, E Jabbour, J Senapati, Z Zeng, GC Issa, H Abbas, C Nasnas, W Qiao, X Huang, G Borthakur, K Chien, FG Haddad, N Pemmaraju, OS Karrar, D Nguyen, M Konopleva, H Kantarjian, F Ravandi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated